BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 29976202)

  • 1. The exon 19-deleted EGFR undergoes ubiquitylation-mediated endocytic degradation via dynamin activity-dependent and -independent mechanisms.
    Wang T; Zhang J; Wang S; Sun X; Wang D; Gao Y; Zhang Y; Xu L; Wu Y; Wu Y; Liu F; Liu X; Liu S; Zhang Y; Wang Y; Zou L; Liu H
    Cell Commun Signal; 2018 Jul; 16(1):40. PubMed ID: 29976202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynasore-induced potent ubiquitylation of the exon 19 deletion mutant of epidermal growth factor receptor suppresses cell growth and migration in non-small cell lung cancer.
    Wang T; Wang D; Zhang Y; Zhang J; Sun X; Wu Y; Wang S; Zhang Y; Xu L; Kong Q; Gao Y; Wu Y; Liu F; Liu S; Zhang Y; Lei T; Liu H
    Int J Biochem Cell Biol; 2018 Dec; 105():1-12. PubMed ID: 30268747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P130Cas attenuates epidermal growth factor (EGF) receptor internalization by modulating EGF-triggered dynamin phosphorylation.
    Kang YS; Kim W; Huh YH; Bae J; Kim JS; Song WK
    PLoS One; 2011; 6(5):e20125. PubMed ID: 21625594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential parsing of EGFR endocytic flux among parallel internalization pathways in lung cancer cells with EGFR-activating mutations.
    Walsh AM; Lazzara MJ
    Integr Biol (Camb); 2014 Mar; 6(3):312-23. PubMed ID: 24445374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasomal deubiquitylase activity enhances cell surface recycling of the epidermal growth factor receptor in non-small cell lung cancer.
    Wang S; Wang T; Yang Q; Cheng S; Liu F; Yang G; Wang F; Wang R; Yang D; Zhou M; Duan C; Zhang Y; Liu H; Dai Z; Tian K; Liu S
    Cell Oncol (Dordr); 2022 Oct; 45(5):951-965. PubMed ID: 36129611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src.
    Chung BM; Raja SM; Clubb RJ; Tu C; George M; Band V; Band H
    BMC Cell Biol; 2009 Nov; 10():84. PubMed ID: 19948031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of EGFR endocytosis by dynamin depletion reveals that EGFR signaling occurs primarily at the plasma membrane.
    Sousa LP; Lax I; Shen H; Ferguson SM; De Camilli P; Schlessinger J
    Proc Natl Acad Sci U S A; 2012 Mar; 109(12):4419-24. PubMed ID: 22371560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ubiquitin-specific protease USP2a prevents endocytosis-mediated EGFR degradation.
    Liu Z; Zanata SM; Kim J; Peterson MA; Di Vizio D; Chirieac LR; Pyne S; Agostini M; Freeman MR; Loda M
    Oncogene; 2013 Mar; 32(13):1660-9. PubMed ID: 22710717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterodimerization of the epidermal-growth-factor (EGF) receptor and ErbB2 and the affinity of EGF binding are regulated by different mechanisms.
    Johannessen LE; Haugen KE; østvold AC; Stang E; Madshus IH
    Biochem J; 2001 May; 356(Pt 1):87-96. PubMed ID: 11336639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non-Small Cell Lung Cancer Patients.
    Choi YW; Jeon SY; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Koh YW; Han JH; Sheen SS
    Am J Clin Oncol; 2018 Apr; 41(4):385-390. PubMed ID: 26967328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockout of c-Cbl slows EGFR endocytic trafficking and enhances EGFR signaling despite incompletely blocking receptor ubiquitylation.
    Crotchett BLM; Ceresa BP
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00756. PubMed ID: 33811466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation.
    Tamirat MZ; Koivu M; Elenius K; Johnson MS
    PLoS One; 2019; 14(9):e0222814. PubMed ID: 31536605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGF receptor ubiquitination is not necessary for its internalization.
    Huang F; Goh LK; Sorkin A
    Proc Natl Acad Sci U S A; 2007 Oct; 104(43):16904-9. PubMed ID: 17940017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptors destined for the nucleus are internalized via a clathrin-dependent pathway.
    De Angelis Campos AC; Rodrigues MA; de Andrade C; de Goes AM; Nathanson MH; Gomes DA
    Biochem Biophys Res Commun; 2011 Aug; 412(2):341-6. PubMed ID: 21821003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyubiquitination of the epidermal growth factor receptor occurs at the plasma membrane upon ligand-induced activation.
    Stang E; Johannessen LE; Knardal SL; Madshus IH
    J Biol Chem; 2000 May; 275(18):13940-7. PubMed ID: 10788520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocytosis and lysosomal targeting of epidermal growth factor receptors are mediated by distinct sequences independent of the tyrosine kinase domain.
    Opresko LK; Chang CP; Will BH; Burke PM; Gill GN; Wiley HS
    J Biol Chem; 1995 Mar; 270(9):4325-33. PubMed ID: 7876194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGF‑stimulated AKT activation is mediated by EGFR recycling via an early endocytic pathway in a gefitinib‑resistant human lung cancer cell line.
    Nishimura Y; Takiguchi S; Ito S; Itoh K
    Int J Oncol; 2015 Apr; 46(4):1721-9. PubMed ID: 25653196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells.
    Shao G; Wang R; Sun A; Wei J; Peng K; Dai Q; Yang W; Lin Q
    Mol Cancer; 2018 Feb; 17(1):24. PubMed ID: 29455656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bif-1 suppresses breast cancer cell migration by promoting EGFR endocytic degradation.
    Runkle KB; Meyerkord CL; Desai NV; Takahashi Y; Wang HG
    Cancer Biol Ther; 2012 Aug; 13(10):956-66. PubMed ID: 22785202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
    Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
    Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.